Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14766MR)

This product GTTS-WQ14766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14490MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ9464MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ4050MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ13629MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ5402MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ4660MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ9735MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ251MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW